Zoldria (zoledronic acid) Injection is indicated for the treatment of hypercalcemia of malignancy.
Multiple Myeloma and Bone Metastases of Solid Tumors - Zoldria is indicated for the treatment of patients with multiple myeloma and patients with ocumented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
Zoldria is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months.

Zoldria Injection

Composition
Each vial contains Zoledronic acid monohydrate equivalent to Zoledronic acid anhydrous 4 mg as sterile freeze dried powder for reconstitution with 5ml of Sterile Water for Injection IP




Indications and Usage
Hypercalcemia of Malignancy - Zoldria (zoledronic acid) Injection is indicated for the treatment of hypercalcemia of malignancy.
Multiple Myeloma and Bone Metastases of Solid Tumors - Zoldria is indicated for the treatment of patients with multiple myeloma and patients with ocumented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Storage Condition to be Given
2°c to 8°c